Peptides for neurodegeneration prevention — what research has explored across Alzheimer's, Parkinson's, ALS

This is the most honest framing to start with, because neurodegeneration research — and the peptide research adjacent to it — often gets discussed in ways that outrun the evidence considerably, and the gap between what the research has explored and what any individual can reasonably do with that exploration is wider here than in almost any other area in longevity and brain health medicine.

The conditions grouped under neurodegeneration share a family of mechanisms but are not the same disease, and they matter differently to different people asking this question. Alzheimer's disease, which accounts for 60 to 80 percent of dementia diagnoses, is characterized pathologically by amyloid-beta plaques and neurofibrillary tau tangles — protein aggregations that accumulate over years or decades before symptoms emerge. The amyloid hypothesis has dominated research for thirty years and, after a string of failed drug trials targeting amyloid, produced two approvals — aducanumab and lecanemab — that reduce amyloid burden measurably but whose clinical meaningfulness remains contested and whose access is severely constrained by cost, infusion requirements, and safety monitoring burden. Parkinson's disease involves the loss of dopaminergic neurons in the substantia nigra, driven in part by alpha-synuclein aggregation (Lewy bodies), with motor symptoms that respond well to dopamine replacement for years before the disease progresses beyond what replacement can address. ALS — amyotrophic lateral sclerosis — involves the progressive loss of both upper and lower motor neurons and is one of the most rapidly progressing and least treatable neurodegenerative conditions; TDP-43 protein aggregation and mitochondrial dysfunction are prominent features. Frontotemporal dementia involves tau or TDP-43 pathology affecting the frontal and temporal lobes with behavioral and language symptoms often preceding memory loss. Vascular dementia — caused by cerebrovascular disease — is the second most common form and has the most direct connection to modifiable cardiovascular risk factors.

The shared mechanisms that cut across these conditions are the reason the peptide research landscape treats them in overlapping ways: protein aggregation that disrupts cellular function, mitochondrial dysfunction that starves neurons of energy, neuroinflammation driven by activated microglia, impaired autophagy that fails to clear protein debris, and vascular contributors that reduce cerebral blood flow and nutrient delivery. Address any of these upstream, the theory goes, and you may slow or delay the downstream pathology. That theory is mechanistically coherent. Whether it translates to clinical benefit in humans — particularly in people without established disease — is the part that is largely unresolved.

Cerebrolysin is a porcine brain-derived peptide complex — it contains a mixture of low-molecular-weight peptides and amino acids derived from pig brain tissue — that has been in clinical use in Eastern Europe and parts of Asia for stroke rehabilitation and dementia for decades. Clinical trials in Alzheimer's disease and post-stroke cognitive impairment, conducted primarily in European and Asian centers, have shown modest improvements in cognitive measures. The evidence base is considered insufficient by US and Western European standards for approval — the FDA has not approved Cerebrolysin, and access in the US requires compounding or importation. The mechanism is thought to involve neurotrophic factor-like activity: Cerebrolysin may support BDNF, NGF, and other factors that promote neuronal survival and synaptic function. It is one of the few peptide approaches in this space with actual clinical trial data in neurodegenerative conditions, even if those trials don't meet the evidentiary bar that Western regulatory agencies require.

Cortexin is a similar tradition — a peptide complex derived from bovine cerebral cortex, developed and used in Russia. Like Cerebrolysin, it's thought to exert neurotrophic-like effects and has been used in stroke, traumatic brain injury, and cognitive decline contexts in its country of origin. The evidence base is similarly limited by Western standards. Both Cerebrolysin and Cortexin represent a research tradition that took neuroprotective peptide biology seriously before the Western research community did, but with trial designs and regulatory contexts that make their data difficult to directly apply.

Humanin is a mitochondria-derived peptide — it is encoded in the mitochondrial genome rather than the nuclear genome, which is itself a remarkable biological feature — that has attracted attention for preclinical neuroprotective effects. In animal models of Alzheimer's disease, Humanin administration reduced amyloid-beta toxicity and neuronal death. The mechanism appears to involve multiple pathways: anti-apoptotic signaling, IGF-1 receptor modulation, and mitochondrial protection. Humanin levels decline with age in humans, which has made it interesting as a potential longevity biomarker and potential therapeutic target. The evidence in humans is preclinical extrapolation at this stage; there are no clinical trials demonstrating neuroprotective benefit in humans.

PACAP — pituitary adenylate cyclase-activating polypeptide — is a neuropeptide with remarkably broad preclinical neuroprotective data. In animal models, PACAP has shown protective effects across stroke, Parkinson's disease, Alzheimer's disease, and traumatic brain injury. The mechanisms are multiple and overlapping: PACAP reduces neuroinflammation, inhibits neuronal apoptosis, supports mitochondrial function, and modulates alpha-synuclein processing in ways that may be relevant to Parkinson's pathology. The challenge is delivery: PACAP does not cross the blood-brain barrier well by peripheral administration, which limits the clinical translation of a preclinical literature that is genuinely impressive. Intranasal delivery routes are being explored as a strategy to bypass this. PACAP is not FDA-approved for any neurological indication and is not available in standard clinical settings in the US.

Semax is a synthetic ACTH analog developed in Russia that has been researched for its influence on BDNF — brain-derived neurotrophic factor, the signaling protein central to synaptic plasticity, learning, and neuronal survival. BDNF declines with age and is implicated in cognitive aging and neurodegenerative vulnerability. Semax intranasal administration in animal models has shown increased BDNF expression and protection in stroke models. Limited human data, primarily from Russian studies in stroke and cognitive impairment contexts, show modest cognitive effects. Selank, a related peptide, shares some of these neuromodulatory properties with an additional anxiolytic dimension through GABAergic pathways and possible influence on neurosteroid balance. Neither is FDA-approved; both are available through compounding routes with limited Western clinical evidence.

Dihexa is a small peptide derived from angiotensin IV that has shown striking effects on synaptic density and memory in preclinical models — effects described in some animal research as exceeding those of BDNF itself in certain tests. The mechanism involves hepatocyte growth factor signaling and the Met receptor, which plays a role in synaptic formation. The preclinical results have attracted significant interest in longevity and cognitive optimization communities. The human evidence is essentially absent. Dihexa is not FDA-approved and has not been through clinical trials. The gap between preclinical impressiveness and clinical reality in neurodegeneration is wide enough — amyloid-targeted drugs took thirty years to produce even contested approvals — that dihexa's preclinical data should be held with appropriate epistemic caution.

FGL — a fragment of neural cell adhesion molecule (NCAM) — has been researched for neural repair and neuroprotection in animal models of brain injury and neurodegeneration. Its mechanism involves the FGFR1 receptor and downstream signaling relevant to synaptic maintenance and repair. Preclinical data is interesting; human data is essentially absent.

NAD+ precursors — NMN and NR — occupy a different category. They are not peptides but are frequently co-discussed in brain health optimization contexts. Mitochondrial dysfunction is central to neurodegenerative pathology, and NAD+ is a cofactor essential to mitochondrial energy production. NAD+ levels decline with age across tissues including neurons. Human trials with NMN and NR have demonstrated that oral supplementation raises cellular NAD+ levels; whether this translates to neuroprotective benefit in humans has not been established in controlled trials, but the mechanism has enough biological support to have attracted serious academic interest and ongoing trials.

BPC-157 in neurological contexts is an interesting area of preclinical research. Animal studies have explored its effects on blood-brain barrier integrity, neuroinflammation, and recovery from brain injury. The blood-brain barrier dysfunction that occurs in neurodegeneration allows peripheral inflammatory signals to enter the CNS and amplify neuroinflammation; a peptide that supports barrier integrity might have relevance here. This is preclinical biology at this stage.

The conventional neurology approach to neurodegeneration is more limited than most people recognize until they're inside the system. For Alzheimer's, donepezil and memantine address symptoms (cholinesterase inhibition and NMDA antagonism) without modifying the underlying pathology — they are treatments of cognitive symptoms, not of the disease. For Parkinson's, carbidopa-levodopa and dopamine agonists are effective for motor symptoms for years, but the underlying neurodegeneration continues. For ALS, riluzole and edaravone modestly slow progression; the newer antisense oligonucleotide therapy targeting SOD1 mutations is meaningful for that genetic subset. For FTD, there are no disease-modifying treatments. The honest picture of the disease-modifying landscape for neurodegeneration is that it remains thin, and the people working in longevity medicine are not wrong to be looking for upstream approaches — they are right to be looking, and wrong if they mistake the search for an answer.

The foundational interventions for cognitive preservation have an evidence base that no peptide in this space currently matches. Cardiovascular exercise — particularly sustained aerobic exercise — has the most consistent and robust association with preserved cognitive function and reduced dementia risk of any intervention tested in humans. The mechanisms are multiple: cerebral blood flow, BDNF, neurogenesis in the hippocampus, reduced neuroinflammation, improved sleep architecture. Sleep is the second pillar: the glymphatic clearance of amyloid-beta happens primarily in slow-wave sleep, and chronic sleep disruption is now recognized as a significant modifiable risk factor for Alzheimer's pathology accumulation. Social engagement and cognitive stimulation have epidemiological associations with preserved function that may reflect resilience-building rather than direct neuroprotection. Managing vascular risk factors — hypertension, dyslipidemia, diabetes, smoking — reduces vascular dementia risk directly and may reduce Alzheimer's risk through shared vascular mechanisms. Treating hearing loss, which has emerged as a surprisingly strong modifiable risk factor in longitudinal studies, matters. Reducing alcohol consumption matters. The Mediterranean dietary pattern has the most consistent dietary association with lower dementia risk, probably through combined anti-inflammatory and vascular mechanisms.

If you're asking about neurodegeneration prevention because you've watched family members go through it, the most useful framing is not "what peptide should I take" but "what are the modifiable risk factors in my specific situation, what biomarkers tell me where my risk actually sits, and what interventions — including but not limited to peptides — have enough mechanistic and clinical rationale to include in a monitored, time-bounded approach." That question belongs inside a relationship with a neurologist or with a longevity medicine physician who takes the cognitive angle seriously and will track you over time with appropriate assessments. If cognitive concerns are present now — changes in function, not just changes in fear about function — neurological evaluation is not optional and should not wait.

The peptide research for neurodegeneration is genuine, early, and preliminary. The foundational interventions are real and accessible now. The specialist relationship is what makes the difference between a thoughtful, monitored approach to reducing your risk and a costly, untracked experiment in a domain where the stakes are high and the feedback loops are long.